Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas

British Journal of Cancer

Volumn 108, Issue 7, 2013, Pages 1449-1459

  Salnikov, A V ^a,b   Bretz, N P ^a   Perne, C ^a   Hazin, J ^a   Keller, S ^a   Fogel, M ^c   Herr, I ^b   Schlange, T ^d   Moldenhauer, G ^a   Altevogt, P ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KAPLAN MEDICAL CENTER   (Israel)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SWA11; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD24; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, SCID; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876477826     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.102     Document Type: Article

References (36)

1. Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M (2009) CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol 62: 1117-1122.
2. Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 12: 1241-1251. (Pubitemid 28418954)
3. Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P (1997) CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 89: 3385-3395. (Pubitemid 27229826)
4. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783-10793. (Pubitemid 41715227)
5. Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP (2012) CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 69: 435-448.
6. Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov A, Moldenhauer G, Kristiansen G, Altevogt P (2011) CD24 promotes tumor-cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 29: 27-38.
7. Bretz NP, Salnikov AV, Perne C, Keller S, Wang X, Mierke CT, Fogel M, Erbe-Hofmann N, Schlange T, Moldenhauer G, Altevogt P (2012) CD24 controls Src/STAT3 activity in human tumors. Cell Mol Life Sci 69(22): 3863-3879.
8. Fang X, Zheng P, Tang J, Liu Y (2010) CD24: from A to Z. Cell Mol Immunol 7: 100-103.
9. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P (2000) The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 60: 6714-6722.
10. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H (2007) Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282: 18634-18644. (Pubitemid 47100243)
11. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G (2012) Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 1: 28-37.
12. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ (2002) Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62: 1462-1470. (Pubitemid 34407808)
13. Jackson D, Waibel R, Weber E, Bell J, Stahel RA (1992) CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 52: 5264-5270.
14. Jaggupilli A, Elkord E (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012: 708036.
15. Kay R, Rosten PM, Humphries RK (1991) CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol 147: 1412-1416.
16. Kristiansen G, Machado E, Bretz N, Rupp C, Winzer KJ, Konig AK, Moldenhauer G, Marme F, Costa J, Altevogt P (2010) Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest 90: 1102-1116.
17. Kristiansen G, Sammar M, Altevogt P (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255-262. (Pubitemid 40585311)
18. Mierke CT, Bretz N, Altevogt P (2011) Contractile forces contribute to increased GPI-anchored receptor CD24 facilitated cancer cell invasion. J Biol Chem 286: 34858-34871.
19. Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D (2011) CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 71: 3802-3811.
20. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20: 460-470.
21. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3: 76-99.
22. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4: 413-415.
23. Runz S, Mierke CT, Joumaa S, Behrens J, Fabry B, Altevogt P (2008) CD24 induces localization of beta1 integrin to lipid raft domains. Biochem Biophys Res Commun 365: 35-41. (Pubitemid 350110573)
24. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N (2008) Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 68: 2803-2812. (Pubitemid 351556279)
25. Schabath H, Runz S, Joumaa S, Altevogt P (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119: 314-325. (Pubitemid 43210700)
26. Schnell R, Katouzi AA, Linnartz C, Schoen G, Drillich S, Hansmann ML, Schiefer D, Barth S, Zangemeister-Wittke U, Stahel RA, Diehl V, Engert A (1996) Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. Int J Cancer 66: 526-531. (Pubitemid 26178174)
27. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: 278-287.
28. Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W (1999) CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol 58: 795-802. (Pubitemid 29372834)
29. Shapira S, Shapira A, Starr A, Kazanov D, Kraus S, Benhar I, Arber N (2011) An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology 140: 935-946.
30. Shuptrine CW, Surana R, Weiner LM (2012) Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 22: 3-13.
31. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D (2006) The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 66: 1917-1922.
32. Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X, Li Z, Bai Y, Wang Y, Zhong Q, Yi T, Qian Z, Wei Y (2009) Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 11: 642-652.
33. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12: 237-251.
34. Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H, Jiang B (2010) CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 101: 112-119.
35. Wolterink S, Moldenhauer G, Fogel M, Kiefel H, Pfeifer M, Luttgau S, Gouveia R, Costa J, Endell J, Moebius U, Altevogt P (2010) Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 70: 2504-2515.
36. Woodward WA, Sulman EP (2008) Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 27: 459-470.